PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer

NCT02331927 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
150
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Ulm

Collaborators